Cargando…

Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology

INTRODUCTION: Labcorp’s DNA Identification division offers HLA typing at various levels of resolution using commercially available kits as well as lab developed assays. A patient sample was received by the lab requiring HLA typing for a disease association screen, and was found to have anomalous HLA...

Descripción completa

Detalles Bibliográficos
Autores principales: Peavy, Lydia, Norvell, Brian, Liu, Haipeng, Steege, Eline, Williams, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476937/
http://dx.doi.org/10.1093/stcltm/szad047.023
_version_ 1785101039209283584
author Peavy, Lydia
Norvell, Brian
Liu, Haipeng
Steege, Eline
Williams, Jon
author_facet Peavy, Lydia
Norvell, Brian
Liu, Haipeng
Steege, Eline
Williams, Jon
author_sort Peavy, Lydia
collection PubMed
description INTRODUCTION: Labcorp’s DNA Identification division offers HLA typing at various levels of resolution using commercially available kits as well as lab developed assays. A patient sample was received by the lab requiring HLA typing for a disease association screen, and was found to have anomalous HLA-A results. OBJECTIVES: To investigate a patient typing with results initially showing multiple variants to any known reference sequence. METHODS: This sample was sequenced using a lab developed whole gene assay that utilizes Pacific Biosciences’s® (PacBio) SMRT® NGS sequencing technology on a Sequel® I with LAA2 contig generation. Due to ambiguous results, the sample was repeated for confirmation using the same test, but a more sensitive data pipeline was used. Subreads coming off of the sequencer were converted to high fidelity or Closed Circular Consensus (CCS) reads using the PBAA tool from PacBio®. The sample was also processed with the GenDx NGSgo®-MX11-3 HLA typing kit with Illumina® sequencing, and the results were sent to GenDx for analysis. RESULTS: Initial testing yielded a high resolution fourth field result for HLA Class I, though the result remained ambiguous. Repeat sequencing resulted three HLA-A alleles with a similar number of CCS reads. The sample was typed as A*01:01:01:01, A*02:01:01:01, and A*02:New which contained a large exonic deletion compared to the A*02:01:01:01 reference. GenDX output confirmed previous findings, indicating a clear first allele of A*01:01:01:01, and reads for the second allele split between A*02:01:01:01 and A*02:New. DISCUSSION: Using Pacbio® sequencing technology with CCS analysis, and confirmation with GenDx technology, it was determined that this individual possesses 3 HLA-A alleles. When aligned with 02:01:01:01, both Pacbio® and GenDx assays determined the A*02:New allele to have a 34bp deletion in exon 2 (position 196-229). As a result of the frame shift caused by this deletion, a premature stop codon was found 43bp downstream from the anomaly, potentially rendering this allele null. Possible explanations for the presence of three HLA-A alleles in one patient include partial allele loss during an autoimmune event, a mutation within a chromosomal duplication of the region, or the patient has undergone a hematopoietic stem cell transplant. [Image: see text]
format Online
Article
Text
id pubmed-10476937
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104769372023-09-05 Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology Peavy, Lydia Norvell, Brian Liu, Haipeng Steege, Eline Williams, Jon Stem Cells Transl Med Preclinical Studies INTRODUCTION: Labcorp’s DNA Identification division offers HLA typing at various levels of resolution using commercially available kits as well as lab developed assays. A patient sample was received by the lab requiring HLA typing for a disease association screen, and was found to have anomalous HLA-A results. OBJECTIVES: To investigate a patient typing with results initially showing multiple variants to any known reference sequence. METHODS: This sample was sequenced using a lab developed whole gene assay that utilizes Pacific Biosciences’s® (PacBio) SMRT® NGS sequencing technology on a Sequel® I with LAA2 contig generation. Due to ambiguous results, the sample was repeated for confirmation using the same test, but a more sensitive data pipeline was used. Subreads coming off of the sequencer were converted to high fidelity or Closed Circular Consensus (CCS) reads using the PBAA tool from PacBio®. The sample was also processed with the GenDx NGSgo®-MX11-3 HLA typing kit with Illumina® sequencing, and the results were sent to GenDx for analysis. RESULTS: Initial testing yielded a high resolution fourth field result for HLA Class I, though the result remained ambiguous. Repeat sequencing resulted three HLA-A alleles with a similar number of CCS reads. The sample was typed as A*01:01:01:01, A*02:01:01:01, and A*02:New which contained a large exonic deletion compared to the A*02:01:01:01 reference. GenDX output confirmed previous findings, indicating a clear first allele of A*01:01:01:01, and reads for the second allele split between A*02:01:01:01 and A*02:New. DISCUSSION: Using Pacbio® sequencing technology with CCS analysis, and confirmation with GenDx technology, it was determined that this individual possesses 3 HLA-A alleles. When aligned with 02:01:01:01, both Pacbio® and GenDx assays determined the A*02:New allele to have a 34bp deletion in exon 2 (position 196-229). As a result of the frame shift caused by this deletion, a premature stop codon was found 43bp downstream from the anomaly, potentially rendering this allele null. Possible explanations for the presence of three HLA-A alleles in one patient include partial allele loss during an autoimmune event, a mutation within a chromosomal duplication of the region, or the patient has undergone a hematopoietic stem cell transplant. [Image: see text] Oxford University Press 2023-09-04 /pmc/articles/PMC10476937/ http://dx.doi.org/10.1093/stcltm/szad047.023 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Preclinical Studies
Peavy, Lydia
Norvell, Brian
Liu, Haipeng
Steege, Eline
Williams, Jon
Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title_full Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title_fullStr Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title_full_unstemmed Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title_short Abstract 22 Anomalous HLA-A Typing Found in Patient Using PacBio Sequencing Technology
title_sort abstract 22 anomalous hla-a typing found in patient using pacbio sequencing technology
topic Preclinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476937/
http://dx.doi.org/10.1093/stcltm/szad047.023
work_keys_str_mv AT peavylydia abstract22anomaloushlaatypingfoundinpatientusingpacbiosequencingtechnology
AT norvellbrian abstract22anomaloushlaatypingfoundinpatientusingpacbiosequencingtechnology
AT liuhaipeng abstract22anomaloushlaatypingfoundinpatientusingpacbiosequencingtechnology
AT steegeeline abstract22anomaloushlaatypingfoundinpatientusingpacbiosequencingtechnology
AT williamsjon abstract22anomaloushlaatypingfoundinpatientusingpacbiosequencingtechnology